Sermorelin is the synthetic version of the biologically active portion of growth hormone releasing hormone (GHRH). Consisting of the first 29 amino acids of the 44-amino acid native GHRH molecule, it retains full biological potency for stimulating pituitary GH release.
Research Applications
GH deficiency diagnostics, pediatric growth research, anti-aging and GH restoration studies, and pituitary function assessment.
Dosage Information (Research Use)
Historical clinical protocols: 100-300 mcg subcutaneously, typically at bedtime. Research use only.
Reconstitution & Handling
Standard BAC water reconstitution. More fragile than modified GHRH analogs — handle carefully and use promptly after reconstitution.
Half-Life & Pharmacokinetics
Approximately 10-20 minutes — significantly shorter than modified GHRH analogs due to DPP-IV degradation.
Reported Observations in Literature
Extensive safety data from clinical use: injection site reactions, facial flushing, headache. Generally well-tolerated.
Key Research References
- Prakash A, Goa KL. “Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.” BioDrugs. 1999